A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Source: View publication →
In patients with acute ischemic stroke caused by a proximal anterior circulation occlusion, endovascular treatment administered within 6 hours of symptom onset significantly improved functional independence at 90 days without increasing mortality or the risk of symptomatic hemorrhage.
Key Findings
Study Design
Study Limitations
Clinical Significance
The MR CLEAN trial revolutionized stroke neurology by definitively proving the clinical superiority of endovascular thrombectomy—when added to standard medical therapy—for acute ischemic stroke with large vessel occlusion. By demonstrating a profound 13.5% absolute increase in functional independence without elevating the risk of mortality or catastrophic hemorrhage, the trial catalyzed a global reorganization of stroke care systems, establishing rapid triage to thrombectomy-capable centers as the new standard of care.
Historical Context
Prior to MR CLEAN, three major randomized trials (IMS III, SYNTHESIS Expansion, and MR RESCUE) failed to demonstrate a clinical benefit for endovascular stroke therapy. These preceding failures were largely attributed to delayed times to reperfusion, the use of older and less effective first-generation thrombectomy devices (e.g., Merci retriever), and a failure to mandate baseline vascular imaging (CTA/MRA) to confirm a targetable large vessel occlusion. MR CLEAN learned from these missteps by strictly requiring imaging-proven proximal occlusions and utilizing newer, highly effective stent-retriever technology. Its decisively positive results triggered the early termination of several concurrent trials (ESCAPE, EXTEND-IA, SWIFT PRIME, and REVASCAT), which immediately corroborated its findings and permanently altered stroke management guidelines.
Guided Discussion
High-yield insights from every perspective
What neuroanatomical territories are at risk in a proximal anterior circulation occlusion (e.g., MCA M1 segment), and what is the pathophysiological concept of the 'ischemic penumbra' that justifies reperfusion therapy within the 6-hour window?
Key Response
Understanding the MCA territory (motor/sensory face and arm, speech if dominant) and the penumbra (salvageable, hypoperfused tissue surrounding the irreversibly infarcted core) is fundamental to understanding why rapid endovascular thrombectomy restores neurological function and prevents the core from expanding.
In the MR CLEAN trial, the vast majority of patients received IV alteplase before endovascular intervention. How does this 'bridging' approach affect the clinical workflow, and does the consideration for thrombectomy delay the administration of IV thrombolytics in the emergency department?
Key Response
Residents must master acute stroke codes. The standard of care dictates that endovascular evaluation or imaging should never delay IV tPA administration if the patient is eligible. Bridging therapy was the standard tested in MR CLEAN, emphasizing parallel rather than sequential workflow.
The MR CLEAN trial relied primarily on NCCT and CTA for patient selection rather than advanced perfusion imaging like CTP or MRI, yet still showed profoundly positive results. How does the presence of robust collateral circulation on CTA influence the success of endovascular therapy, and why might advanced perfusion imaging be less critical in this early (<6 hour) window?
Key Response
Fellows must understand the evolution of stroke imaging. In the early window (0-6h), 'time is brain,' and simple CTA to confirm LVO and assess collaterals is generally sufficient. Good collaterals sustain the penumbra, meaning if recanalization is achieved quickly, clinical benefit is highly likely without needing time-consuming perfusion scans.
Given the definitive benefit of intraarterial treatment demonstrated in MR CLEAN, how should regional stroke systems of care be reorganized regarding 'drip-and-ship' versus 'mothership' routing protocols for EMS transport of suspected large vessel occlusion strokes?
Key Response
Attendings are responsible for systems-level stroke care. MR CLEAN sparked a major practice shift, prompting ongoing debates and protocol changes about whether EMS should bypass primary stroke centers to take suspected LVOs directly to comprehensive centers (mothership) to minimize time to puncture, balanced against potential delays in getting IV tPA.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The primary analysis of MR CLEAN utilized a proportional odds model to detect a shift across the entire ordinal scale of the modified Rankin Scale (mRS), rather than a simple dichotomization (e.g., mRS 0-2 vs 3-6). What are the statistical advantages of the ordinal shift analysis in stroke trials, and what key underlying assumption must be met for this model to be valid?
Key Response
Methodologically, the proportional odds model increases statistical power by capturing functional transitions across all states, allowing for smaller sample sizes. However, it relies heavily on the proportional odds assumption (the odds ratio is constant across all cutoffs of the mRS), which researchers must validate to ensure the model's appropriateness.
MR CLEAN was a pragmatic, open-label trial with blinded outcome assessment (PROBE design). As a peer reviewer assessing threats to internal validity, how does the lack of a sham procedure in the control arm potentially introduce performance bias during the post-procedural intensive care phase, and does the blinded mRS assessment fully mitigate this?
Key Response
Without a sham intervention, treating clinicians know the assignment. This can bias post-stroke care decisions (e.g., blood pressure management, early rehab, or withdrawal of life-sustaining therapies). While blinded outcome assessment mitigates detection bias, it cannot erase the performance bias introduced during the 90 days of clinical care.
Based on the MR CLEAN findings and subsequent confirmatory trials, how should stroke clinical practice guidelines update the Class of Recommendation and Level of Evidence for mechanical thrombectomy in patients with acute anterior circulation LVO presenting within 6 hours, and what specific baseline criteria must be met?
Key Response
MR CLEAN was the pivotal catalyst that prompted the AHA/ASA to upgrade endovascular therapy to a Class I, Level of Evidence A recommendation. Guidelines stipulate it for patients with anterior circulation LVO (ICA or M1), baseline mRS 0-1, NIHSS >= 6, ASPECTS >= 6, and treatment initiation within 6 hours of symptom onset.
Clinical Landscape
Noteworthy Related Trials
ESCAPE Trial
Tested
Endovascular thrombectomy plus standard care
Population
Acute ischemic stroke patients with anterior circulation occlusion within 12 hours
Comparator
Standard care alone
Endpoint
Functional independence (mRS 0-2) at 90 days
EXTEND-IA Trial
Tested
Endovascular thrombectomy (Solitaire FR) plus IV t-PA
Population
Ischemic stroke patients with proximal occlusion and salvageable brain tissue on CT perfusion
Comparator
IV t-PA alone
Endpoint
Reperfusion at 24 hours and early neurologic improvement
SWIFT PRIME Trial
Tested
Stent-retriever thrombectomy plus IV t-PA
Population
Acute ischemic stroke patients with proximal anterior circulation occlusion treated within 6 hours
Comparator
IV t-PA alone
Endpoint
Functional independence (mRS 0-2) at 90 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis